DELRAY BEACH, Fla., Sept. 29, 2014 (GLOBE NEWSWIRE) — VeriTeQ Corporation (“VeriTeQ”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has received an order for 100 units of its new Q Inside readers for breast implants. The Q Inside reader identifies VeriTeQ’s Q Inside Safety Technology within breast implants and other medical devices.

VeriTeQ recently announced the launch of its new readers, the Q Inside Reader + and the Q Inside Reader XR +, which identify its Q Inside Safety Technology™ micro-transponders used for unique medical device identification. VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer.

Commenting on the order, Scott R. Silverman, VeriTeQ’s Chairman and CEO, stated, “We continue to evolve our technology on a customer-by-customer basis to meet unique needs and technology desires. Our new Q Inside reader is just an example of how we meet our customer’s needs with new and enhanced design.”

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ’s Form 10-K, filed on April 15, 2014, and Forms 10-Q, filed on August 20, 2014, May 14, 2014, and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

VeriTeQ
Allison Tomek, 561-846-7003